Loading...

We've got a brand new version of Simply Wall St! Try it out

Navamedic

OB:NAVA
Snowflake Description

Adequate balance sheet with poor track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NAVA
OB
NOK303M
Market Cap
  1. Home
  2. NO
  3. Pharmaceuticals & Biotech
Company description

Navamedic ASA, a medtech and pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in Northern European region. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Navamedic has significant price volatility in the past 3 months.
NAVA Share Price and Events
7 Day Returns
31.6%
OB:NAVA
-2.2%
Europe Pharmaceuticals
2.6%
NO Market
1 Year Returns
148%
OB:NAVA
6.8%
Europe Pharmaceuticals
-9.1%
NO Market
NAVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Navamedic (NAVA) 31.6% 61.3% 69.1% 148% 154.8% 129.6%
Europe Pharmaceuticals -2.2% 0.5% 2.3% 6.8% 10.1% 3.1%
NO Market 2.6% 8% 2.6% -9.1% 31.3% 13.2%
1 Year Return vs Industry and Market
  • NAVA outperformed the Pharmaceuticals industry which returned 6.8% over the past year.
  • NAVA outperformed the Market in Norway which returned -9.1% over the past year.
Price Volatility
NAVA
Industry
5yr Volatility vs Market

NAVA Value

 Is Navamedic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Navamedic to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Navamedic.

OB:NAVA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 6.7%
Perpetual Growth Rate 10-Year NO Government Bond Rate 1.8%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OB:NAVA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year NO Govt Bond Rate 1.8%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.703 (1 + (1- 23%) (8.88%))
0.834
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.76% + (0.834 * 5.96%)
6.73%

Discounted Cash Flow Calculation for OB:NAVA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Navamedic is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

OB:NAVA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (NOK, Millions) Source Present Value
Discounted (@ 6.73%)
2020 2.27 Est @ -48.23% 2.13
2021 1.52 Est @ -33.23% 1.33
2022 1.17 Est @ -22.74% 0.97
2023 0.99 Est @ -15.39% 0.77
2024 0.89 Est @ -10.24% 0.64
2025 0.83 Est @ -6.64% 0.56
2026 0.80 Est @ -4.12% 0.51
2027 0.78 Est @ -2.36% 0.46
2028 0.77 Est @ -1.12% 0.43
2029 0.77 Est @ -0.26% 0.40
Present value of next 10 years cash flows NOK8.00
OB:NAVA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NOK0.77 × (1 + 1.76%) ÷ (6.73% – 1.76%)
NOK15.73
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NOK15.73 ÷ (1 + 6.73%)10
NOK8.20
OB:NAVA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NOK8.00 + NOK8.20
NOK16.20
Equity Value per Share
(NOK)
= Total value / Shares Outstanding
= NOK16.20 / 10.87
NOK1.49
OB:NAVA Discount to Share Price
Calculation Result
Value per share (NOK) From above. NOK1.49
Current discount Discount to share price of NOK27.90
= -1 x (NOK27.90 - NOK1.49) / NOK1.49
-1771.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Navamedic is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Navamedic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Navamedic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:NAVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in NOK NOK0.34
OB:NAVA Share Price ** OB (2019-09-13) in NOK NOK27.9
Europe Pharmaceuticals Industry PE Ratio Median Figure of 54 Publicly-Listed Pharmaceuticals Companies 23.94x
Norway Market PE Ratio Median Figure of 149 Publicly-Listed Companies 13.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Navamedic.

OB:NAVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:NAVA Share Price ÷ EPS (both in NOK)

= 27.9 ÷ 0.34

81.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Navamedic is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.
  • Navamedic is overvalued based on earnings compared to the Norway market.
Price based on expected Growth
Does Navamedic's expected growth come at a high price?
Raw Data
OB:NAVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 81.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 38 Publicly-Listed Pharmaceuticals Companies 1.78x
Norway Market PEG Ratio Median Figure of 110 Publicly-Listed Companies 0.72x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Navamedic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Navamedic's assets?
Raw Data
OB:NAVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in NOK NOK8.78
OB:NAVA Share Price * OB (2019-09-13) in NOK NOK27.9
Europe Pharmaceuticals Industry PB Ratio Median Figure of 115 Publicly-Listed Pharmaceuticals Companies 2.87x
Norway Market PB Ratio Median Figure of 238 Publicly-Listed Companies 1.13x
OB:NAVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:NAVA Share Price ÷ Book Value per Share (both in NOK)

= 27.9 ÷ 8.78

3.18x

* Primary Listing of Navamedic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Navamedic is overvalued based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess Navamedic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Navamedic has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NAVA Future Performance

 How is Navamedic expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Navamedic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Navamedic expected to grow at an attractive rate?
  • Unable to compare Navamedic's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Navamedic's earnings growth to the Norway market average as no estimate data is available.
  • Unable to compare Navamedic's revenue growth to the Norway market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OB:NAVA Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.3%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
Norway Market Earnings Growth Rate Market Cap Weighted Average 15.1%
Norway Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:NAVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:NAVA Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-06-30 189 7 4
2019-03-31 187 1 9
2018-12-31 184 -36 7
2018-09-30 177 -20 -20
2018-06-30 178 -11 -13
2018-03-31 222 41 -20
2017-12-31 258 59 -16
2017-09-30 294 43 3
2017-06-30 315 29 4
2017-03-31 292 -13 -9
2016-12-31 274 -15 -11
2016-09-30 258 -8 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Navamedic is high growth as no earnings estimate data is available.
  • Unable to determine if Navamedic is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:NAVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Navamedic Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:NAVA Past Financials Data
Date (Data in NOK Millions) EPS *
2019-06-30 0.34
2019-03-31
2018-12-31 0.67
2018-09-30
2018-06-30 -1.19
2018-03-31
2017-12-31 -1.43
2017-09-30 0.31
2017-06-30 0.40
2017-03-31 -0.87
2016-12-31 -1.04
2016-09-30 -2.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Navamedic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Navamedic's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Navamedic's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Navamedic's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Navamedic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Navamedic has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NAVA Past Performance

  How has Navamedic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Navamedic's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Navamedic's year on year earnings growth rate has been positive over the past 5 years.
  • Navamedic has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Navamedic has become profitable in the last year making it difficult to compare the Europe Pharmaceuticals industry average.
Earnings and Revenue History
Navamedic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Navamedic Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:NAVA Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 188.86 3.85 30.93
2019-03-31 186.84 9.19 30.63
2018-12-31 184.02 7.28 30.33
2018-09-30 177.37 -19.71 29.85
2018-06-30 177.90 -12.93 28.00
2018-03-31 222.39 -20.14 30.17
2017-12-31 257.92 -15.54 29.83
2017-09-30 294.36 3.34 30.94
2017-06-30 314.63 4.38 31.62
2017-03-31 291.68 -9.23 31.47
2016-12-31 274.30 -10.66 31.33
2016-09-30 258.07 -27.85 31.06
2016-06-30 254.37 -30.02 30.09
2016-03-31 247.30 -16.58 28.33
2015-12-31 248.35 -10.93 26.08
2015-09-30 244.91 -4.21 22.55
2015-06-30 242.19 0.74 20.57
2015-03-31 242.02 0.77 19.74
2014-12-31 223.07 -0.72 19.43
2014-09-30 204.05 0.69 18.72
2014-06-30 182.00 -1.76 19.29
2014-03-31 160.65 -2.66 19.95
2013-12-31 151.77 -1.27 20.19
2013-09-30 133.68 -0.40 20.31
2013-06-30 117.52 -0.92 20.17
2013-03-31 102.10 -0.81 19.12
2012-12-31 88.68 -3.25 18.13
2012-09-30 83.17 -4.49 19.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Navamedic has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Navamedic used its assets less efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Navamedic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Navamedic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Navamedic has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NAVA Health

 How is Navamedic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Navamedic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Navamedic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Navamedic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Navamedic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Navamedic Company Filings, last reported 2 months ago.

OB:NAVA Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 95.42 25.18 6.51
2019-03-31 101.32 28.65 12.75
2018-12-31 99.32 32.58 11.05
2018-09-30 76.90 30.97 16.90
2018-06-30 77.20 28.19 5.68
2018-03-31 80.87 20.16 8.32
2017-12-31 96.70 12.21 30.25
2017-09-30 104.60 15.08 29.60
2017-06-30 109.13 42.57 41.81
2017-03-31 104.25 57.07 15.89
2016-12-31 105.73 58.85 26.80
2016-09-30 95.85 55.58 31.62
2016-06-30 105.05 57.21 32.92
2016-03-31 110.16 51.75 16.33
2015-12-31 118.28 35.89 12.30
2015-09-30 131.12 34.29 10.88
2015-06-30 112.64 11.32 8.24
2015-03-31 109.44 23.60 4.38
2014-12-31 106.69 27.38 6.18
2014-09-30 103.29 29.08 5.98
2014-06-30 105.18 17.87 7.55
2014-03-31 104.63 12.86 2.39
2013-12-31 107.26 12.48 2.24
2013-09-30 105.46 16.26 4.37
2013-06-30 104.12 10.25 5.11
2013-03-31 103.69 0.00 4.89
2012-12-31 97.12 0.00 3.62
2012-09-30 99.97 0.00 4.68
  • Navamedic's level of debt (26.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (17.1% vs 26.4% today).
  • Debt is well covered by operating cash flow (29%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on Navamedic's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Navamedic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Navamedic has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NAVA Dividends

 What is Navamedic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Navamedic dividends.
If you bought NOK2,000 of Navamedic shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Navamedic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Navamedic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:NAVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 3%
Norway Market Average Dividend Yield Market Cap Weighted Average of 115 Stocks 4.5%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.5%
Norway Bottom 25% Dividend Yield 25th Percentile 2.5%
Norway Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OB:NAVA Past Annualized Dividends Data
Date (Data in NOK) Dividend per share (annual) Avg. Yield (%)
2012-05-04 0.000 0.000
2012-04-12 0.000 0.000
2011-10-21 0.000 0.000
2011-10-20 0.000 0.000
2011-08-25 0.000 0.000
2011-08-24 0.000 0.000
2011-03-24 0.000 0.000
2011-02-04 0.000 0.000
2010-05-05 1.000 14.682
2010-04-12 1.000 13.797

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Navamedic has not reported any payouts.
  • Unable to verify if Navamedic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Navamedic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Navamedic has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Navamedic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Navamedic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Navamedic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NAVA Management

 What is the CEO of Navamedic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kathrine Andreassen
AGE 53
TENURE AS CEO 0.7 years
CEO Bio

Ms. Kathrine Gamborg Andreassen has been Chief Executive Officer of Navamedic ASA since January 1, 2019. Ms. Andreassen served as the Chair of the Board at Navamedic ASA since June 07, 2018. Ms. Andreassen is an experienced marketing professional and has held various executive positions in Consumer Health and FmCG (Orkla, Kemetyl). She served as the Chief Executive Officer of Weifa ASA from June 1, 2015 to November 2017. Ms. Andreassen served as Vice President of Consumer Health at Weifa AS since August 2012. She served as Group Marketing & Communication Director of Kemetyl AB. She is an experienced marketing professional and she has held several top management positions within the FMCG, food and health business. She served as a Director of Vistin Pharma ASA since March 26, 2015. Ms. Andreassen has an MSc in Business Strategy & Marketing from the University of Wisconsin.

CEO Compensation
  • Insufficient data for Kathrine to compare compensation growth.
  • Insufficient data for Kathrine to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Management Team Tenure

Average tenure and age of the Navamedic management team in years:

0.7
Average Tenure
51
Average Age
  • The average tenure for the Navamedic management team is less than 2 years, this suggests a new team.
Management Team

Kathrine Andreassen

TITLE
Chief Executive Officer
AGE
53
TENURE
0.7 yrs

Toril Ås

TITLE
Chief Financial Officer
AGE
49
TENURE
3.1 yrs

Mattias Von Hartmann

TITLE
Marketing and Sales Director

Per-Anders Elvertrø

TITLE
Head of Regulatory
AGE
45

Ole Eriksen

TITLE
Chief Operating Officer of Business Development
AGE
59
TENURE
0.6 yrs

Alexander Lidmejer

TITLE
Sales Director
AGE
38
TENURE
0.4 yrs

Magnus Emmoth

TITLE
Chief Executive Officer of Navamedic Medtech AB
AGE
53
TENURE
4.1 yrs
Board of Directors

Terje Bakken

TITLE
Chairman
AGE
53

Jostein Davidsen

TITLE
Director
COMPENSATION
NOK120K
AGE
60
TENURE
2.7 yrs

Inger Solhaug

TITLE
Director

Narve Reiten

TITLE
Director
AGE
58

Cheng Lu

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
14. Feb 19 Buy Toril Ås Individual 14. Feb 19 14. Feb 19 20,000 NOK13.25 NOK265,000
14. Dec 18 Buy Storvestre Solutions AS Company 13. Dec 18 13. Dec 18 10,000 NOK10.05 NOK100,500
13. Dec 18 Buy Nobelsystem Scandinavia AS Company 13. Dec 18 13. Dec 18 25,000 NOK10.11 NOK252,870
05. Dec 18 Buy Nobelsystem Scandinavia AS Company 05. Dec 18 05. Dec 18 25,000 NOK11.04 NOK276,070
21. Nov 18 Buy Kathrine Andreassen Individual 21. Nov 18 21. Nov 18 83,334 NOK12.00 NOK1,000,008
21. Nov 18 Buy Nobelsystem Scandinavia AS Company 21. Nov 18 21. Nov 18 18,000 NOK11.38 NOK204,838
21. Nov 18 Sell Nobelsystem Scandinavia AS Company 21. Nov 18 21. Nov 18 -3,166,667 NOK12.00 NOK-38,000,002
21. Nov 18 Sell Nobelsystem Scandinavia AS Company 21. Nov 18 21. Nov 18 -3,166,667 NOK12.00 NOK-38,000,002
16. Nov 18 Buy Nobelsystem Scandinavia AS Company 16. Nov 18 16. Nov 18 18,000 NOK11.48 NOK206,699
12. Nov 18 Buy Nobelsystem Scandinavia AS Company 12. Nov 18 12. Nov 18 10,000 NOK11.48 NOK114,767
09. Nov 18 Buy Nobelsystem Scandinavia AS Company 09. Nov 18 09. Nov 18 12,000 NOK11.46 NOK137,502
25. Oct 18 Buy Nobelsystem Scandinavia AS Company 25. Oct 18 25. Oct 18 18,000 NOK12.27 NOK220,871
24. Oct 18 Buy Nobelsystem Scandinavia AS Company 24. Oct 18 24. Oct 18 11,000 NOK11.50 NOK126,458
23. Oct 18 Buy Nobelsystem Scandinavia AS Company 23. Oct 18 23. Oct 18 15,000 NOK11.47 NOK172,099
22. Oct 18 Buy Nobelsystem Scandinavia AS Company 22. Oct 18 22. Oct 18 12,000 NOK11.58 NOK138,900
19. Oct 18 Buy Nobelsystem Scandinavia AS Company 19. Oct 18 19. Oct 18 15,000 NOK11.74 NOK176,150
18. Oct 18 Buy Nobelsystem Scandinavia AS Company 18. Oct 18 18. Oct 18 10,000 NOK11.55 NOK115,487
17. Oct 18 Buy Nobelsystem Scandinavia AS Company 17. Oct 18 17. Oct 18 15,000 NOK11.39 NOK170,809
16. Oct 18 Buy Nobelsystem Scandinavia AS Company 16. Oct 18 16. Oct 18 12,000 NOK10.60 NOK127,231
15. Oct 18 Buy Nobelsystem Scandinavia AS Company 15. Oct 18 15. Oct 18 13,000 NOK10.63 NOK138,215
12. Oct 18 Buy Nobelsystem Scandinavia AS Company 12. Oct 18 12. Oct 18 10,000 NOK10.71 NOK107,125
12. Oct 18 Buy Nobelsystem Scandinavia AS Company 12. Oct 18 12. Oct 18 12,000 NOK10.96 NOK131,482
10. Oct 18 Buy Nobelsystem Scandinavia AS Company 10. Oct 18 10. Oct 18 10,000 NOK11.08 NOK110,844
09. Oct 18 Buy Nobelsystem Scandinavia AS Company 01. Oct 18 01. Oct 18 5,000 NOK11.79 NOK58,974
X
Management checks
We assess Navamedic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Navamedic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NAVA News

Simply Wall St News

How Much Of Navamedic ASA (OB:NAVA) Do Insiders Own?

The big shareholder groups in Navamedic ASA (OB:NAVA) have power over the company. … Navamedic is not a large company by global standards. … We can zoom in on the different ownership groups, to learn more about NAVA

Simply Wall St -

What Investors Should Know About Navamedic ASA's (OB:NAVA) Financial Strength

While small-cap stocks, such as Navamedic ASA (OB:NAVA) with its market cap of øre125.0m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Who Owns Navamedic ASA (OB:NAVA)?

I am going to take a deep dive into Navamedic ASA’s (OB:NAVA) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … It also impacts the trading environment of company shares, which is more of a concern for short-term investors.

Simply Wall St -

Who Owns Most Of Navamedic ASA (OB:NAVA)?

In this article, I'm going to take a look at Navamedic ASA’s (OB:NAVA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … View our latest analysis for Navamedic OB:NAVA Ownership_summary May 21st 18 Institutional Ownership In NAVA's case, institutional ownership stands at 14.04%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: NAVA's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Is Navamedic ASA (OB:NAVA) A Sell At Its Current PE Ratio?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for NAVA Price per share = NOK12.75 Earnings per share = NOK0.306 ∴ Price-Earnings Ratio = NOK12.75 ÷ NOK0.306 = 41.7x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … For example, if you are inadvertently comparing riskier firms with NAVA, then NAVA’s P/E would naturally be higher than its peers since investors would reward its lower risk with a higher price.

Simply Wall St -

Does Navamedic ASA's (OB:NAVA) Past Performance Indicate A Stronger Future?

Today I will assess NAVA's recent performance announced on 31 December 2017 and compare these figures to its long-term trend and industry movements. … See our latest analysis for Navamedic Were NAVA's earnings stronger than its past performances and the industry? … I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

What You Must Know About Navamedic ASA's (OB:NAVA) Financial Strength

NAVA has shrunken its total debt levels in the last twelve months, from ØRE58.85M to ØRE12.21M , which is made up of current and long term debt. … Moreover, NAVA has generated ØRE59.04M in operating cash flow in the last twelve months, resulting in an operating cash to total debt ratio of 483.58%, signalling that NAVA’s operating cash is sufficient to cover its debt. … Investors' risk associated with debt is very low with NAVA, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: NAVA has demonstrated its ability to generate sufficient levels of cash flow, while its debt hovers at a safe level.

Simply Wall St -

NAVA Company Info

Description

Navamedic ASA, a medtech and pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in Northern European region. The company operates through two segments, Pharma and Healthcare Products, and Medtech. Its product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices, and other health care products. The company also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, tyrosinemia, maple sirup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, and glutaric aciduria type 1, as well as carbohydrate metabolism, fat metabolism, and renal diseases. In addition, it sells consumer care products consisting non-prescription drugs, pharmaceuticals, and health care products primarily through pharmacies and drugstores. Further, the company offers Sippi, a digital urine meter, which measures biofilm build-up through non-contact capacitive sensor; and Re5-NTS, a treatment concept that uses electrical pulses as treatment in patients with refractory depression. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Lysaker, Norway.

Details
Name: Navamedic ASA
NAVA
Exchange: OB
Founded: 2002
NOK303,208,076
10,867,673
Website: http://www.navamedic.com
Address: Navamedic ASA
Fornebuveien 42-44,
PO Box 107,
Lysaker,
Akershus, 1325,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB NAVA Class A Ordinary Shares Oslo Bors NO NOK 31. Mar 2006
DB N1A Class A Ordinary Shares Deutsche Boerse AG DE EUR 31. Mar 2006
BATS-CHIXE NAVAO Class A Ordinary Shares BATS 'Chi-X Europe' GB NOK 31. Mar 2006
Number of employees
Current staff
Staff numbers
0
Navamedic employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/14 21:06
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/08/23
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.